Dendritic cell immunotherapy in serous ovarian cancer. KU Leuven
Ovarian cancer is the second most important pelvic tumor with limited treatment options in case of relapsing tumors, leading to a poor prognosis. New therapies are needed. Earlier, we developed dendritic cell (DC) immunotherapy for uterine cancers, based on the tumorassociated antigen (TAA) Wilms’ tumor gene 1 (WT1). DCs were produced in the laboratory starting from regular white blood cells from a patient. These DCs were loaded with WT1 in ...